This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Gori, F. Articles by Riggs, B. L. Search for Related Content PubMed PubMed Citation Articles by Gori, F. Articles by Riggs, B. L.

The Expression of Osteoprotegerin and RANK Ligand and the Support of Osteoclast Formation by Stromal-Osteoblast Lineage Cells Is Developmentally Regulated¹

Endocrine Research Unit and Department of Biochemistry (F.G., L.C.H., S.K., B.L.R.) and Molecular Biology (T.C.S.), Mayo Clinic and Mayo Foundation, Rochester, Minnesota 55905; and Amgen, Inc. (C.R.D.), Thousand Oaks, California

Address all correspondence and requests for reprints to: B. Lawrence Riggs, M.D., Mayo Clinic, 200 First Street SW, Plummer North 6, Rochester, Minnesota 55905. E-mail: Riggs.Lawrence{at}Mayo.edu

The one or more molecular mechanisms that determine the obligatory sequence of resorption followed by formation during bone remodeling is unclear. RANK ligand (RANK-L) is an essential requirement for osteoclastogenesis, and its activity is neutralized by binding to the soluble decoy receptor, osteoprotegerin (OPG). Because both molecules are produced by osteoblast lineage cells, we studied their developmental regulation in a conditionally immortalized human marrow stromal (hMS[2–15]) cell line. These cells can simulate the complete developmental sequence from undifferentiated precursor(s) to cells with the complete osteoblast phenotype that are capable of forming mineralized nodules. During osteoblast differentiation, RANK-L messenger RNA levels decreased by 5-fold, whereas OPG messenger RNA levels increased by 7-fold, resulting in a 35-fold change in the RANK-L/OPG ratio. OPG protein also increased by 6-fold. Mouse bone marrow cells generated osteoclast-like cells in coculture with undifferentiated hMS(2–15) cells, but did not when cocultured with hMS(2–15) cells in varying stages of differentiation, unless an excess of RANK-L was added. Thus, undifferentiated marrow stromal cells with a high RANK-L/OPG ratio can initiate and support osteoclastogenesis, but after differentiation to the mature osteoblast phenotype, they cannot. We speculate that the developmental regulation of OPG and RANK-L production by stromal/osteoblast cells contributes to the coordinated sequence of osteoclast and osteoblast differentiation during the bone remodeling cycle.

This article has been cited by other articles:

				C. Galli, Q. Fu, W. Wang, B. R. Olsen, S. C. Manolagas, R. L. Jilka, and C. A. O'Brien Commitment to the Osteoblast Lineage Is Not Required for RANKL Gene Expression J. Biol. Chem., May 8, 2009; 284(19): 12654 - 12662. [Abstract] [Full Text] [PDF]

				M. Biosse-Duplan, B. Baroukh, M. Dy, M.-C. de Vernejoul, and J.-L. Saffar Histamine Promotes Osteoclastogenesis through the Differential Expression of Histamine Receptors on Osteoclasts and Osteoblasts Am. J. Pathol., April 1, 2009; 174(4): 1426 - 1434. [Abstract] [Full Text] [PDF]

				T. L. Andersen, T. E. Sondergaard, K. E. Skorzynska, F. Dagnaes-Hansen, T. L. Plesner, E. M. Hauge, T. Plesner, and J.-M. Delaisse A Physical Mechanism for Coupling Bone Resorption and Formation in Adult Human Bone Am. J. Pathol., January 1, 2009; 174(1): 239 - 247. [Abstract] [Full Text] [PDF]

				A. E. Kearns, S. Khosla, and P. J. Kostenuik Receptor Activator of Nuclear Factor {kappa}B Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease Endocr. Rev., April 1, 2008; 29(2): 155 - 192. [Abstract] [Full Text] [PDF]

				A. D Anastasilakis, D. G Goulis, S. A Polyzos, S. Gerou, V. Pavlidou, G. Koukoulis, and A. Avramidis Acute changes in serum osteoprotegerin and receptor activator for nuclear factor-{kappa}B ligand levels in women with established osteoporosis treated with teriparatide Eur. J. Endocrinol., March 1, 2008; 158(3): 411 - 415. [Abstract] [Full Text] [PDF]

				R. A. Deckelbaum, A. Majithia, T. Booker, J. E. Henderson, and C. A. Loomis The homeoprotein engrailed 1 has pleiotropic functions in calvarial intramembranous bone formation and remodeling Development, January 1, 2006; 133(1): 63 - 74. [Abstract] [Full Text] [PDF]

				A. Rogers and R. Eastell Circulating Osteoprotegerin and Receptor Activator for Nuclear Factor {kappa}B Ligand: Clinical Utility in Metabolic Bone Disease Assessment J. Clin. Endocrinol. Metab., November 1, 2005; 90(11): 6323 - 6331. [Abstract] [Full Text] [PDF]

				S. Lossdorfer, W. Gotz, and A. Jager PTH(1-34) Affects Osteoprotegerin Production in Human PDL Cells in vitro Journal of Dental Research, July 1, 2005; 84(7): 634 - 638. [Abstract] [Full Text] [PDF]

				X.-H. Liu, A. Kirschenbaum, S. Yao, and A. C. Levine Cross-Talk between the Interleukin-6 and Prostaglandin E2 Signaling Systems Results in Enhancement of Osteoclastogenesis through Effects on the Osteoprotegerin/Receptor Activator of Nuclear Factor-{kappa}B (RANK) Ligand/RANK System Endocrinology, April 1, 2005; 146(4): 1991 - 1998. [Abstract] [Full Text] [PDF]

				S. M. Krane Identifying genes that regulate bone remodeling as potential therapeutic targets J. Exp. Med., March 21, 2005; 201(6): 841 - 843. [Abstract] [Full Text] [PDF]

				E. Gazzerro, R. C. Pereira, V. Jorgetti, S. Olson, A. N. Economides, and E. Canalis Skeletal Overexpression of Gremlin Impairs Bone Formation and Causes Osteopenia Endocrinology, February 1, 2005; 146(2): 655 - 665. [Abstract] [Full Text] [PDF]

				M. Heim, O. Frank, G. Kampmann, N. Sochocky, T. Pennimpede, P. Fuchs, W. Hunziker, P. Weber, I. Martin, and I. Bendik The Phytoestrogen Genistein Enhances Osteogenesis and Represses Adipogenic Differentiation of Human Primary Bone Marrow Stromal Cells Endocrinology, February 1, 2004; 145(2): 848 - 859. [Abstract] [Full Text] [PDF]

				V. Viereck, C. Grundker, S. Blaschke, B. Niederkleine, H. Siggelkow, K.-H. Frosch, D. Raddatz, G. Emons, and L. C. Hofbauer Raloxifene Concurrently Stimulates Osteoprotegerin and Inhibits Interleukin-6 Production by Human Trabecular Osteoblasts J. Clin. Endocrinol. Metab., September 1, 2003; 88(9): 4206 - 4213. [Abstract] [Full Text] [PDF]

				O. Sezer, U. Heider, I. Zavrski, C. A. Kuhne, and L. C. Hofbauer RANK ligand and osteoprotegerin in myeloma bone disease Blood, March 15, 2003; 101(6): 2094 - 2098. [Abstract] [Full Text] [PDF]

				V. Katavic, I. K. Lukic, N. Kovacic, D. Grcevic, J. A. Lorenzo, and A. Marusic Increased Bone Mass Is a Part of the Generalized Lymphoproliferative Disorder Phenotype in the Mouse J. Immunol., February 1, 2003; 170(3): 1540 - 1547. [Abstract] [Full Text] [PDF]

				E M Gravallese Bone destruction in arthritis Ann Rheum Dis, November 1, 2002; 61(90002): ii84 - 86. [Abstract] [Full Text] [PDF]

				K. Janssens and W. Van Hul Molecular genetics of too much bone Hum. Mol. Genet., October 1, 2002; 11(20): 2385 - 2393. [Abstract] [Full Text] [PDF]

				V. Geoffroy, M. Kneissel, B. Fournier, A. Boyde, and P. Matthias High Bone Resorption in Adult Aging Transgenic Mice Overexpressing Cbfa1/Runx2 in Cells of the Osteoblastic Lineage Mol. Cell. Biol., September 1, 2002; 22(17): 6222 - 6233. [Abstract] [Full Text] [PDF]

				S. Khosla Minireview: The OPG/RANKL/RANK System Endocrinology, December 1, 2001; 142(12): 5050 - 5055. [Abstract] [Full Text] [PDF]

				B. Burguera, L. C. Hofbauer, T. Thomas, F. Gori, G. L. Evans, S. Khosla, B. L. Riggs, and R. T. Turner Leptin Reduces Ovariectomy-Induced Bone Loss in Rats Endocrinology, August 1, 2001; 142(8): 3546 - 3553. [Abstract] [Full Text] [PDF]